PCOS Is Now Called PMOS: The 2026 Name Change Explained (For Patients and Doctors)

PCOS Renamed PMOS - Polyendocrine Metabolic Ovarian Syndrome Medical Insights

The short answer

On 12 May 2026, polycystic ovary syndrome (PCOS) was officially renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS). The change was published in The Lancet following an 11-year global consensus process involving 56 academic, clinical and patient organisations and more than 22,000 contributors, including over 14,300 people living with the condition.

What this means for you, in one line: the condition is the same, your diagnosis is still valid, your treatment does not change — but the name now describes what the condition actually is.

What it means clinically: the emphasis shifts from an ovarian imaging finding to a whole-body endocrine and metabolic disorder, which is what the evidence has supported for over two decades.

Book Consultation

What each part of "PMOS" means

Poly-endocrine

the condition is driven by multiple interacting hormonal disturbances, not one. These include hyperinsulinaemia and insulin resistance, androgen excess (ovarian and adrenal), and neuroendocrine disturbance at the level of GnRH pulsatility with a consequently raised LH:FSH ratio. Thyroid dysfunction and hyperprolactinaemia frequently coexist and must be actively excluded.

Metabolic

insulin resistance is present in a substantial majority of patients, independent of BMI. Compensatory hyperinsulinaemia directly amplifies ovarian theca cell androgen production and suppresses hepatic sex hormone binding globulin (SHBG), which raises free testosterone. This is the mechanistic core of the syndrome, and it is why metabolic treatment improves reproductive symptoms.

Ovarian syndrome

the ovarian consequences remain defining: ovulatory dysfunction, oligomenorrhoea or amenorrhoea, and anovulatory infertility. The link to the ovary is retained because it remains clinically central. What has been dropped is the misleading word "cystic".

Why the old name was a problem

The term "polycystic ovary syndrome" caused four specific, documented harms:

  • The "cysts" are not cysts.

    The follicles seen on ultrasound in this condition are not pathological cysts. They are normal antral follicles that have arrested at an early stage of development because of disordered folliculogenesis. Calling them cysts caused decades of patient anxiety about ovarian pathology that does not exist, and prompted unnecessary imaging, referrals and even surgical opinions.

  • It made a supporting feature sound like the defining feature.

    Polycystic ovarian morphology (PCOM) is one of three Rotterdam criteria — and under the 2023 international guideline it is not even required for diagnosis when irregular cycles and hyperandrogenism are both present. Yet the name told patients and non-specialist clinicians that ovarian appearance was the whole diagnosis. This is a major driver of the common misconception that "no cysts on scan means no PCOS."

  • It obscured the metabolic risk.

    Insulin resistance, dyslipidaemia, increased type 2 diabetes risk and increased cardiovascular risk are core features of the syndrome. A name centred on ovarian appearance meant metabolic screening was routinely deferred or skipped — particularly in adolescents and in lean patients, where clinicians did not "see" a metabolic phenotype.

  • It fragmented care.

    Because the name is gynaecological, the condition was treated as a gynaecological problem. In practice it requires input across endocrinology, dermatology, metabolic medicine, mental health and reproductive medicine. The naming contributed directly to the observed delay in diagnosis and to patients being passed between specialties without a coordinating clinician.

What has NOT changed

This is where most confusion is arising, so it is worth being explicit.

  • Diagnostic criteria are unchanged. The 2023 International Evidence-Based Guideline criteria remain in force. The name changed; the definition did not.

  • Your existing diagnosis remains valid. No patient needs to be re-diagnosed or re-tested because of the rename.

  • Treatment is unchanged. Lifestyle intervention, combined oral contraceptives, anti-androgens, metformin, inositol and letrozole all retain their existing evidence base and indications.

  • PCOD is still not a formal diagnosis. "PCOD" (polycystic ovarian disease) was never an internationally recognised diagnostic entity — it is colloquial usage common in India. It has not been renamed, because it was never officially named.

  • Coding and records will transition gradually. Expect a period where laboratory reports, referral letters, insurance documentation and ICD coding continue to use PCOS. Both terms will appear in parallel for some time.

For gynaecologists: the practical implications

  • Terminology in practice. During the transition period, the pragmatic approach in Indian clinical practice is to write "PMOS (formerly PCOS)" in correspondence and reports for at least the next 12–24 months. This preserves clarity with referring clinicians, insurers and patients who know the old term, while normalising the new one.

  • Reframe the consultation. The rename is a genuine clinical opportunity. It gives you a natural opening to explain to a patient — often for the first time — that this is not an ovarian cyst problem but a metabolic-endocrine condition with long-term cardiometabolic consequences. In practice this materially improves engagement with lifestyle intervention, which remains first-line therapy and has the poorest adherence of any component of management.

  • Audit your metabolic screening. If the rename prompts one change in your practice, make it this: check what proportion of your PMOS patients have had an OGTT (not just a fasting glucose), a fasting lipid profile, and a blood pressure recorded in the last 12 months. Under-screening of metabolic risk is the single most common gap in real-world PMOS care, and it is more common in lean patients and adolescents.

  • Correct the "no cysts, no diagnosis" error. The rename directly helps here. Under the 2023 guideline, where irregular menstrual cycles and hyperandrogenism are both present in an adult, neither ultrasound nor AMH is required for diagnosis. A normal-appearing ovary does not exclude PMOS.

  • Adolescents. Note that PCOM on ultrasound should not be used as a diagnostic criterion until 8 years post-menarche, and AMH is likewise not recommended in adolescents due to poor specificity. Pubertal physiology mimics the syndrome. See our detailed article on adolescent diagnosis.

Why this matters particularly in India

India carries the highest burden of this condition in South Asia. A nationwide study of over 9,800 Indian women reported a prevalence of up to 19.6% — close to double the global estimate of approximately 1 in 8 women.

Two features of the Indian population make the metabolic reframing especially relevant:

South Asian phenotype

Indian women develop insulin resistance and visceral adiposity at lower BMI thresholds than European populations. This is why Asian-specific BMI cut-offs are used (overweight ≥23 kg/m², obese ≥25 kg/m²). A patient with a BMI of 24 who would be labelled "normal weight" by Western criteria may already have significant insulin resistance. Under the old name, these patients were routinely told their PCOS was "mild" because they were not visibly overweight.

Diagnostic delay and stigma

In a global survey of ethnic Indian women with the condition, the three most commonly reported concerns were irregular periods, "cysts on the ovaries", and excess facial hair. That "cysts" ranked second — as a primary concern, not merely a finding — illustrates precisely the anxiety the old terminology generated. In the same survey, 64% reported at least one co-morbidity, most commonly anxiety or depression.

Frequently asked questions

Is PMOS a new disease?

No. PMOS is the new official name for the condition previously called PCOS. It is the same condition, with the same diagnostic criteria and the same treatments. Only the name has changed.

Do I need to be re-tested or re-diagnosed?

No. If you have been diagnosed with PCOS, you have PMOS. Your diagnosis, reports and treatment plan remain valid.

When exactly did the name change?

The consensus was published in The Lancet on 12 May 2026, following an 11-year process involving 56 organisations and more than 22,000 people worldwide.

Why was PCOS renamed?

Because the name was inaccurate and harmful. The follicles seen on ultrasound are not true cysts; the name hid the condition's metabolic and endocrine nature; and it contributed to delayed diagnosis, fragmented care and stigma.

Is PMOS the same as PCOD?

No. PCOD is an informal term used commonly in India; it has never been an internationally recognised diagnosis. PMOS is the current official name for the condition formerly called PCOS.

Will my doctor and my lab reports use the new name?

Gradually. Expect both terms to appear in parallel for the next one to two years while records, coding systems and laboratory templates are updated. Many clinicians, including us, currently write "PMOS (formerly PCOS)" to avoid confusion.

Does the treatment change now?

No. Lifestyle management, combined oral contraceptives, anti-androgens, metformin, inositol and letrozole for ovulation induction all remain unchanged in their indications and evidence base.

Does this mean I don't have ovarian cysts?

Correct — and you likely never did in the pathological sense. What is seen on ultrasound is an increased number of small, immature follicles that have stopped developing. They are not the type of cyst that requires removal or surgical concern.

What is the full form of PMOS?

PMOS stands for Polyendocrine Metabolic Ovarian Syndrome.

PCOS ka naya naam kya hai?

PCOS ko ab PMOS — Polyendocrine Metabolic Ovarian Syndrome kaha jaata hai. Yeh naam 12 May 2026 ko officially badla gaya. Bimari wahi hai, sirf naam badla hai. Aapka diagnosis aur treatment same rahega.

Is PMOS more serious than PCOS?

No. It is the same condition. The new name does not mean the condition is more severe — it means the name now correctly describes the hormonal and metabolic problems that were always part of it.

My report says PCOS. Is my report outdated?

No. Your report is still valid. Laboratories and hospitals will take time to update their systems, so you will see both terms for the next year or two.

Do I need to tell my insurance company about the name change?

No. Insurance coding systems will update over time. Your existing documentation remains valid.

Is PCOD also renamed?

No. PCOD was never an official medical diagnosis — it is a term used informally, mainly in India. Only PCOS has been officially renamed, to PMOS.

Consult

If you have been diagnosed with PCOS or PMOS, or you have irregular periods, unexplained weight gain, acne, excess facial hair, or difficulty conceiving, a structured hormonal and metabolic assessment is the right starting point.

Dr. Shruti Shah's PMOS & Hormonal Health Clinic

1st floor, Darshan Orthopaedic Surgical Clinic & Maternity Home, Swami Vivekanand Rd, opp. Milap PVR Theatre, Malad West, Mumbai 400064

Phone: +91 93215 05185

Sources

Dr. Shruti Shah - Obstetrician and Gynecologist

Medical Reviewer: Dr. Shruti Shah

MBBS (Nair Hospital), MS OB-GYN (JJ Hospital), DNB (Seth GS Medical College)

Dr. Shruti Shah is a leading Obstetrician, Gynecologist, and Hormonal Specialist in Mumbai with over 21 years of clinical experience specializing in PCOS/PMOS management, menstrual disorders, and reproductive health.

Book a Consultation

Schedule an appointment with Dr. Shruti Shah for a dedicated PCOS/PMOS and hormonal health assessment.

  • Location

    1st floor, Darshan Orthopaedic Surgical Clinic & Maternity Home, Swami Vivekanand Rd, opp. Milap PVR Theatre, Mumbai, Maharashtra 400064

  • Phone

    +91 93215 05185

  • Email

    drshrutisclinic@gmail.com